Want to see HK:6618 full AI Analyst Report?
6618 Stock Chart & Stats
HK$36.74
HK$0.78(2.11%)
At close: 4:00 PM EDT
HK$36.74
HK$0.78(2.11%)
Day’s Range― - ―
52-Week RangeHK$31.84 - HK$71.70
Previous CloseN/A
Volume4.55M
Average Volume (3M)7.54M
Market Cap
HK$118.43B
Enterprise ValueHK$49.29B
Total Cash (Recent Filing)HK$47.41B
Total Debt (Recent Filing)HK$874.69M
Price to Earnings (P/E)16.4
Beta1.19
Next Earnings
Mar 29, 2027EPS Estimate
1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.92
Shares Outstanding3,190,481,000
10 Day Avg. Volume10,110,773
30 Day Avg. Volume7,535,827
Financial Highlights & Ratios
PEG Ratio1.09
Price to Book (P/B)2.65
Price to Sales (P/S)2.17
P/FCF Ratio16.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$65.33Price Target Upside77.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.87
Revenue Forecast (FY)HK$85.70B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And DiversificationStrong product growth combined with a meaningful service business indicates broadening demand across JD Health’s platform. This diversified revenue base can support durable expansion, reduce reliance on one category, and provide operating leverage as transaction and service volumes increase.
Sustained Margin ExpansionNine consecutive quarters of year-over-year margin improvement provide evidence that profitability gains are becoming embedded in the operating model. Better scale, procurement optimization, and expense discipline can strengthen earnings quality and support sustained reinvestment.
Conservative Balance Sheet And LiquidityExtremely low leverage and substantial liquidity give JD Health financial resilience through changing demand and investment cycles. The balance sheet can fund platform development, offline expansion, and technology investment while limiting interest burden and refinancing pressure.
Bears Say
Free Cash Flow ResetThe move to zero free cash flow weakens near-term capital flexibility despite strong operating cash generation. If investment or working-capital demands remain elevated, less internally generated cash will be available for expansion, buybacks, or protection against operating volatility.
Regulatory Headwinds In SupplementsRegulatory tightening and counterfeit-brand exposure can require greater compliance, assortment control, and customer-trust rebuilding across supplements. These pressures may constrain category growth and execution for several quarters, even if compliant operators benefit over time.
AI Monetization Remains UnprovenRapid user adoption has not yet translated into a proven independent revenue stream, leaving the return on ongoing AI investment uncertain. JD Health may need continued spending before monetization becomes material, which could delay the technology’s contribution to durable earnings.
JD Health International, Inc. News
6618 FAQ
What was JD Health International, Inc.’s price range in the past 12 months?
JD Health International, Inc. lowest stock price was HK$31.84 and its highest was HK$71.70 in the past 12 months.
What is JD Health International, Inc.’s market cap?
JD Health International, Inc.’s market cap is HK$118.43B.
When is JD Health International, Inc.’s upcoming earnings report date?
JD Health International, Inc.’s upcoming earnings report date is Mar 29, 2027 which is in 152 days.
How were JD Health International, Inc.’s earnings last quarter?
JD Health International, Inc. released its earnings results on Aug 13, 2026. The company reported HK$1.259 earnings per share for the quarter, missing the consensus estimate of HK$1.376 by -HK$0.118.
Is JD Health International, Inc. overvalued?
According to Wall Street analysts JD Health International, Inc.’s price is currently Undervalued.
Does JD Health International, Inc. pay dividends?
JD Health International, Inc. does not currently pay dividends.
What is JD Health International, Inc.’s EPS estimate?
JD Health International, Inc.’s EPS estimate is 1.13.
How many shares outstanding does JD Health International, Inc. have?
JD Health International, Inc. has 3,190,481,000 shares outstanding.
What happened to JD Health International, Inc.’s price movement after its last earnings report?
JD Health International, Inc. reported an EPS of HK$1.259 in its last earnings report, missing expectations of HK$1.376. Following the earnings report the stock price went up 1.698%.
Which hedge fund is a major shareholder of JD Health International, Inc.?
Currently, no hedge funds are holding shares in HK:6618
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JD Health International, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.03%
12-Months-Change
Fundamentals
Return on Equity
10.15%
Trailing 12-Months
Asset Growth
13.17%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
JD Health International, Inc.
JD Health International Inc., functioning as an investment holding entity, runs an expansive digital healthcare platform across the People's Republic of China. The company supplies a diverse range of pharmaceutical and wellness products, such as over-the-counter and prescription medications, medical devices, and health supplements. These goods are distributed through both direct sales and an extensive online retail pharmacy network. Beyond product offerings, its comprehensive service suite includes virtual medical consultations, patient referrals to hospitals and doctors, health screening programs, genetic testing, and beauty care services. Additionally, it develops intelligent healthcare and wellness management solutions, alongside providing technical support and advertising services. The platform also facilitates access to various medical provisions, including general health examinations, cosmetic medical procedures, vaccination bookings, dental treatments, and nucleic acid testing. Incorporated in 2018 and headquartered in Beijing, People's Republic of China, JD Health International Inc. is a subsidiary of JD Jiankang Limited.
6618 Stock 12 Month Forecast
Average Price Target
HK$65.33
▲(77.82% Upside)
Technical Analysis
Kindstar Globalgene Technology, Inc.
―
Jinxin Fertility Group Ltd.
―
C-MER Eye Care Holdings Limited
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―